Skip to product information
Zentra-Injekt HP, 5-pack

Zentra-Injekt HP, 5-pack

Incl. VAT

Presentation: 5 x 5 ml infusion concentrate

Composition: Magnesium chloride hexahydrate, calcium chloride dihydrate, potassium chloride, water for injection

Prescription status: prescription only

Storage: store at room temperature

Shelf life: 1 year after manufacture

After completing your order, you will receive a link through which you can securely upload your prescription.

Anmeldung erforderlich
PRODUCT INFORMATION

Composition:

  • Magnesium chloride hexahydrate 181 mg
  • Calcium chloride dihydrate 60 mg
  • Potassium chloride 1.5 mg
  • Glycine 10 mg
  • Water for injection to 5 ml

Administration: i.v., always prepare the infusion solution freshly, dilute in 100 ml of 0.9% NaCl

Infusion time: 20 to 30 minutes

Therapy interval: 1-2 times per week, based on the patient's health condition 

Duration of treatment: 6-8 weeks, based on the patient's health condition 

Storage: 15 – 25°C 

Shelf life: 1 year after manufacture

Side effects: ACE inhibitors, angiotensin II blockers, cardiac glycosides, potassium-sparing diuretics, loop diuretics, thiazides, and NSAIDs such as ibuprofen increase potassium levels, while corticosteroids lower potassium levels.

THERAPY RECOMMENDATION

Positive Effects:

  • Zentra-Injekt contains the basic minerals magnesium, calcium, and potassium. 98% of the potassium cation is located inside the cell.
  • Every cell needs potassium to be metabolically active.
  • Magnesium improves cellular potassium utilization.
  • This means sodium reduction and simultaneous increase in potassium intake.
  • Magnesium: see monoinfusion
  • Calcium regulates muscle contraction (antagonist to magnesium).
  • Calcium is involved in neurotransmission in the nervous system through calcium channel-dependent release of neurotransmitters.
  • Calcium activates the blood clotting system.
  • Calcium stabilizes cell membranes.

Therapeutic Recommendations:There is evidence that the properties of the substances contained in the product can have a positive effect on health disorders of the mentioned indications:

  • for electrolyte deficiencies
  • for latent acidosis and inflammatory processes
  • blood pressure regulation, hypertension, cardiac arrhythmias, stroke prevention
  • for oxidative or nitrosative stress: NADPH oxidase is inhibited, ROS formation is inhibited, intracellular calcium is reduced
  • for type 2 diabetes mellitus, insulin resistance: insulin sensitivity is increased
  • for deficits in energy metabolism (exhaustion, chronic fatigue, CFS, muscle weakness)
  • for menopausal symptoms, PMS, and restlessness
  • in pain therapy, including migraine, analgesic
  • for Rheumatoid Arthritis

Contraindications:Do not use in children under 6 years of age. For impaired kidney, liver, or heart function, and for albumin deficiency, an adjustment of the individual dose is recommended.

Patients taking beta-blockers have an increased risk of a decompensated cardiovascular reaction, as beta-blockers inhibit the effect of adrenaline (emergency medical treatment).

Patients with a tendency to allergic reactions and/or with diseases based on histamine release (e.g., asthma) should be questioned about known allergens in accordance with the principles of therapeutic due diligence.

General Information:

  • A good potassium level depends on sodium and magnesium intake. Magnesium improves cellular potassium utilization.
  • The American Heart Association recommends a daily dose of 4.7 g
    potassium+ per day and only 1.5 g sodium. The molar sodium-potassium ratio should be < 1. This means sodium reduction and simultaneous increase in potassium intake.
  • Acidosis leads to a shift of potassium from intracellular to extracellular. Consequences include neuromuscular dysfunctions, states of exhaustion, muscle weakness, muscle cramps, paresthesias, and cardiac arrhythmias.
  • Calcium is essential for the mineralization of bone tissue and dental hard tissue. Calcium status is regulated by three hormones: 1,25-(OH)2-cholecalciferol (calcitriol), parathormone, and calcitonin.
  • The widespread undersupply of calcium and magnesium in the population leads, with an increase in parathyroid hormone (PTH), to an increased conversion of calcidiol (25-OH-vitamin D) into calcitriol (1,25-OH-vitamin D3). The resulting shift in the balance towards calcitriol is shown in the laboratory findings as an increase in the vitamin D quotient (normal < 1). In addition to demineralization of the bone, the excessively formed calcitriol increases the influx of calcium into the cells. This results in pro-inflammatory and pro-oxidative changes in cellular metabolism, such as an increase in cytokine expression and the increased formation of reactive oxygen species (radicals). The intracellular calcium influx is accompanied by an efflux of potassium and magnesium. This loss of intracellular potassium and magnesium enhances the pro-oxidative effect of calcitriol. Source: Löffler, The Calcium-Magnesium-Deficient Population: Vitamin
    D3 Alone Is Not Enough. OM & Ernährung 2014; 148: 2–11.
  • Oxidative stress and pro-inflammatory processes block detoxification pathways, leading to an increase in toxins and detoxification metabolites and, consequently, again to oxidative stress, and can cause degenerative diseases.

Shipping Information

NATIONAL:

  • Standard shipping: €9.95 incl. VAT
  • Free shipping on orders over €200.00 (does not apply to refrigerated goods and express shipments)
  • Refrigerated and express shipping: €25.95 incl. VAT

Note: If individual products are unavailable, partial deliveries may occur, incurring no additional shipping costs.
Any requested partial deliveries will be charged.

WITHIN THE EU:
For shipments to countries in EU Zone 1, we charge logistics costs of €75.00 (incl. VAT).

For shipments to countries in EU Zone 2, we charge logistics costs of €105.00 (incl. VAT).

THIRD COUNTRIES:
The customer is asked to inquire about the logistics costs incurred for the respective country.

References

We have researched the literature references with the greatest possible care. Nevertheless, we assume no liability for the completeness and up-to-dateness of the study information. Many of the therapy options mentioned in the product information are based on findings obtained from animal or human cell cultures, animal experiments, observational studies, and to a lesser extent randomized controlled trials (RCTs).
The study situation for complementary medicines is subject to continuous development, which can sometimes lead to different results. We therefore recommend that therapists always carefully check the current study situation before using such preparations.

The literature references for this product are in progress and will be published shortly.